Novo Nordisk’s primary business is the development, production, and sale of pharmaceutical products, primarily focused on diabetes care. We maintain a strong commitment to improving the lives of people with diabetes and other chronic diseases. Our portfolio includes insulin, GLP-1 analogs, obesity medications, and other biopharmaceuticals. We also provide services and solutions to support healthcare professionals in the treatment of diabetes and other chronic diseases. Novo Nordisk is dedicated to advancing scientific research and innovation to improve patient outcomes and quality of life.
Source: Great Place To Work® 2024 Australia National Employee Engagement Study
Start by earning Great Place To Work-Certified™ status through the Trust Index™ employee survey and the Culture Brief. Once Certified, eligible organizations are considered for Best Workplaces™ lists during the qualification period.
Best Workplaces™ recognition is based on employee feedback collected through the Trust Index™ survey, supported by your Culture Brief submission. This keeps the focus on the real employee experience rather than marketing claims.
Eligibility starts with becoming Great Place to Work-Certified™. Your organization also needs to meet the list’s timing and participation requirements, so your results fall within the qualification window for that Best Workplaces™ list.
The Culture Brief is a short questionnaire about your organization to support your survey results. The Culture Audit goes deeper, typically asking for more detailed descriptions and evidence of your workplace practices.
